DepoCyt®
Only FDA-approved drug for lymphomatous meningitis
Serious complication of certain cancers
Largely untreated patient population
Orphan drug status
US re-launch by Chiron
EC marketing approval
Launch anticipated in 2002
New US marketing strategy
Earlier treatment
Emphasis on quality of life
Estimated US sales of US$50m
Phase IV studies to expand label to solid tumours
(Chiron, Elan, Nippon-Shinyaku)